Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against antibiotic resistance
- Important step forward for nosocomial pneumonia treatment -
Vienna, Austria, April 24, 2017 – Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years. Murepavadin (POL7080), the first member of the OMPTA class – currently in Phase II and soon expected to enter Phase III – is being developed for the treatment of the most severe Pseudomonas aeruginosa (PA) infection – nosocomial pneumonia (including hospital-acquired and ventilator-associated pneumonia) – a disease with a death rate of 20-50%.